Eurocine Vaccines presented at BOS Virtual 2021
On 1 July 2021, CEO Hans Arwidsson gave a presentation at BOS, Biotech Outsourcing Strategies, Virtual 2021, which is an event arranged by Bio2Business Ltd.,…
Interviews with CEO Hans Arwidsson
Eurocine Vaccines AB has published two interviews with CEO Hans Arwidsson in connection with the ongoing preferential issue of units. The interviews, which have partly…
Eurocine Vaccines prepares to evaluate two more vaccine candidates
As part of its portfolio strategy, Eurocine Vaccines is actively searching for new vaccine candidates to expand the portfolio. Of the currently ongoing discussions with…
Eurocine Vaccines presentation från Aktieportföljen Live
Eurocine Vaccines presenterade verksamheten, framtidsplaner, vaccinmarknaden och samarbeten, bland annat relaterat till en vaccinkandidat mot klamydia, på Aktieportföljen Live den 26 maj 2021.Read More
Eurocine Vaccines publishes interim report for July 2020 – March 2021
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes the interim report for July 2020 to March 2021. Below is a summary of the report. The full…
Eurocine Vaccines´ Adjuvant Technology Endocine™ is evaluated with a vaccine candidate against COVID-19
Eurocine Vaccines has signed a Material Transfer Agreement regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19.Read More
Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
Today, Eurocine Vaccines AB (“Eurocine Vaccines”) announces the completion of knowledge transfer and preparations for the development of the manufacturing process to secure the active…
Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate
Eurocine Vaccines AB (“Eurocine Vaccines”) confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate. The study confirms that an adapted…
Eurocine Vaccines publishes half-year report for July-December 2020
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes an interim report for the first half year of 2020. Below is a summary of the report. The…
Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
Eurocine Vaccines AB (“Eurocine Vaccines” or the “Company”) has today selected Biovian Oy, Turku, Finland, (“Biovian”) as the contract developer for the Company's vaccine candidate…